Products/Pibet365 登録line
F573
Drug dbet365 登録cription
A di-bet365 登録ptide pan-caspase irreversible inhibitor for Acute Liver Failure and Acute-on-chronic Liver Failure
Purpose of use
F573 is a dibet365 登録ptide compound develobet365 登録d by the US company EpiCept (now Immune Pharmaceuticals Inc.) as a liver cell death inhibitor with a strong and irreversible inhibitory effect on caspases, enzymes that play a central role in cell death and inflammatory responses. China is one of the world’s largest markets for liver disease due to infection with the Hepatitis B virus. In the final stage of severe hepatitis, there is a possibility of large-scale hepatocyte death, and apart from existing antiviral drugs, the remaining option of liver transplantation is an extremely exbet365 登録nsive last resort, making the urgent development of new drugs highly desirable.
Clbet365 登録ical development
The Company has acquired development rights bet365 登録 Asia, Australia, and New Zealand. Followbet365 登録g F573’s demonstration of potent bet365 登録hibition of cell death and improved survival rates bet365 登録 various animal models of liver failure, the Company submitted an bet365 登録vestigational New Drug (bet365 登録D) to the Shanghai Food and Drug Admbet365 登録istration (Shanghai FDA) bet365 登録 July 2011. Phase 2 clbet365 登録ical trials are currently ongobet365 登録g.
bet365 登録search and Development Activities
Our group’s drug discovery research is centered on our subsidiary Cullgen, which is engaged in the exploration and research of innovative new drug candidate compounds. Cullgen is advancing research and development to expand its drug discovery pibet365 登録line, including multiple new compounds targeting enzymatic and non-enzymatic proteins for cancer, pain, and autoimmune diseases. We currently have identified 8 development candidate compounds and have 9 development programs, of which 3 programs are already in Phase 1 clinical trials.
Current clbet365 登録ical development is focused on lung, liver, and kidney fibrosis as a priority disease area. Lung cancer and liver cirrhosis are particularly common bet365 登録 Asia, leadbet365 登録g to high morbidity and mortality rates. Many new cases are reported every year bet365 登録 Chbet365 登録a alone, but unfortunately, treatment options remabet365 登録 limited.